Long-term clinical value and outcome of riociguat in chronic thromboembolic pulmonary hypertension
Under a Creative Commons license
open access
Abbreviations
6MWD
6-minute walking distance
AE
adverse event
BPA
balloon pulmonary angioplasty
CO
cardiac output
CTEPH
chronic thromboembolic pulmonary hypertension
CHEST
Chronic Thromboembolic Pulmonary Hypertension Soluble Guanylate Cyclase-Stimulator Trial
CW
clinical worsening
e.g.
exempli gratiā
ERA
endothelin receptor antagonist
FC
functional class
HR
hazards regression
i.e.
id est
mPAP
mean pulmonary arterial pressure
NT-proBNP
N-terminal pro brain natriuretic peptide
PAH
pulmonary arterial hypertension
PAP
pulmonary arterial pressure
PEA
pulmonary endarterectomy
PH
pulmonary hypertension
PVR
pulmonary vascular resistance
RAP
right atrial pressure
Residual PH
persistent pulmonary hypertension after PEA
SD
standard deviation
sGC
soluble guanylate cyclase
WHO
World Health Organization
Keywords
Chronic thromboembolic pulmonary hypertension
Riociguat
Clinical outcome
Survival
Clinical worsening
Cited by (0)
© 2019 The Authors. Published by Elsevier B.V.